The development of a green-by-design, two-step, three-enzyme process for the synthesis of a key intermediate in the manufacture of atorvastatin, the active ingredient of the cholesterol lowering drug Lipitor®, is described. The first step involves the biocatalytic reduction of ethyl- 4-chloroacetoacetate using a ketoreductase (KRED) in combination with glucose and a NADP-dependent glucose dehydrogenase (GDH) for cofactor regeneration. The (S) ethyl- ...
[Bergeron, Sophie; Chaplin, David A.; Edwards, John H.; Ellis, Brian S. W.; Hill, Catherine L.; Holt-Tiffin, Karen; Knight, Jonathan R.; Mahoney, Thomas; Osborne, Andrew P.; Ruecroft, Graham Organic Process Research and Development, 2006 , vol. 10, # 3 p. 661 - 665]
